U.S. Food and Drug Administration and European Medicines Agency Reach Landmark Decisions on Critical Path institute’s Clinical Trial Simulation Tool for Alzheimer’s Disease

In a big step forward for Alzheimer’s disease (AD) therapy development, both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have independently reached favorable decisions on the value of Critical Path Institute’s new disease simulation tool for improving trial design in mild and moderate Alzheimer’s disease. The first such instrument to ever receive this regulatory designation, the tool represents an enabling advance to improve the design of future clinical trials in AD. The new tool applies computerized models to simulate “what-if” scenarios for clinical trials.

The goal of this virtual tool is to serve as a public resource for sponsors designing trials of new therapies for AD.Continue reading

Critical Path Institute names Martha Brumfield CEO

The Board of Directors of the Critical Path Institute (C-Path) announced today that Martha Brumfield, Ph.D., has been named interim president and chief executive officer of the organization. Brumfield, C-Path’s former director of International & Regulatory Programs, takes over immediately for Carolyn Compton, M.D., Ph.D., who will be assuming a new position at Arizona State University (ASU).Continue reading


Tucson, Arizona, February 1, 2012– Critical Path Institute (C-Path) announced today that Dr. Carolyn Compton has joined the organization as its new president and chief executive officer. Dr. Compton takes over for Dr. Raymond L. Woosley, C-Path’s founder, who last year announced his intention to step down as President/CEO, and asked the Board of Directors to begin a search for his successor.Continue reading